Search results
May 11, 2018 · Behring, Emil Adolph von (1854–1917) German bacteriologist and pioneer immunologist. In 1901 he received the first Nobel Prize in physiology or medicine for his work on serum therapy, developing immunization against diphtheria (1890) and tetanus (1892) by injections of antitoxins.
Emil Adolf von Behring and a bacteriologist and was awarded the first Nobel Prize in Physiology and Medicine in 1901. He was a brilliant man best known for his discovery of diphtheria and tetanus vaccines. His tetanus vaccine helped save the lives of millions of wounded soldiers during the First World.
Emil von Behring, born Emil Adolf Behring, was a German physiologist who received the 1901 Nobel Prize in Physiology or Medicine, the first one awarded in that field, for his discovery of a diphtheria antitoxin. He was widely known as a "saviour of children", as diphtheria used to be a major cause of child death.
Dec 1, 2022 · By: Maggie Zhou. Published: 2022-12-01. Emil von Behring researched treatments for the common childhood disease diphtheria in Germany in the 1890s and early 1900s. Diphtheria is a lethal disease that infected approximately 40,000 people in Germany between 1886 and 1888 with a general mortality rate of twenty-five percent.
Apr 25, 2024 · In 1913 he introduced toxin–antitoxin mixtures to immunize against diphtheria, a refinement of the immunization technique already in use. He also devised a vaccine for the immunization of calves against tuberculosis. From: Behring, Emil Adolf von in A Dictionary of Scientists ». Subjects: Science and technology.
Apr 10, 2017 · Emil von Behring (1854–1917) discovered passive immu nization as an effective treatment for diphtheria and teta nus. Moreover, he brought this discovery from bench to bedside, and his serum...
Download PDF. Portrait of Emil von Behring (1854-1917), a German physiologist who worked to prove the possibility of transferring immunity against the toxins of tetanus and Diptheria. Behring won the 1901 Nobel Prize for Physiology or Medicine for the development of serum therapies.
